These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 8729519)

  • 41. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ret-proto-oncogene analysis in medullary thyroid carcinoma.
    O'Keeffe DA; Hill AD; Sheahan K; Ryan F; Barton D; Fitzgerald RJ; McDermott EW; O'Higgins NJ
    Ir J Med Sci; 1998; 167(4):226-30. PubMed ID: 9868860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
    Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
    Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation.
    Gimm O; Neuberg DS; Marsh DJ; Dahia PL; Hoang-Vu C; Raue F; Hinze R; Dralle H; Eng C
    Oncogene; 1999 Feb; 18(6):1369-73. PubMed ID: 10022819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
    Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma.
    Eng C; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Thomas GA; Ponder BA
    Cancer Res; 1996 May; 56(9):2167-70. PubMed ID: 8616867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
    Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
    Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas.
    van der Harst E; de Krijger RR; Bruining HA; Lamberts SW; Bonjer HJ; Dinjes WN; Proye C; Koper JW; Bosman FT; Roth J; Heitz PU; Komminoth P
    Int J Cancer; 1998 Oct; 79(5):537-40. PubMed ID: 9761126
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
    Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.
    Miyauchi A; Matsuzuka F; Hirai K; Yokozawa T; Kobayashi K; Kuma S; Kuma K; Futami H; Yamaguchi K
    World J Surg; 2000 Nov; 24(11):1367-72. PubMed ID: 11038208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.
    Elisei R; Cosci B; Romei C; Bottici V; Sculli M; Lari R; Barale R; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3579-84. PubMed ID: 15240649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absence of RET proto-oncogene point mutations in sporadic hyperplastic and neoplastic lesions of the parathyroid gland.
    Padberg BC; Schröder S; Jochum W; Kastendieck H; Roth J; Heitz PU; Komminoth P
    Am J Pathol; 1995 Dec; 147(6):1600-7. PubMed ID: 7495285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
    Acton DS; Velthuyzen D; Lips CJ; Höppener JW
    Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-specific mutations in the tyrosine kinase domain of the RET proto-oncogene in pheochromocytomas of sporadic type.
    Yoshimoto K; Tanaka C; Hamaguchi S; Kimura T; Iwahana H; Miyauchi A; Itakura M
    Endocr J; 1995 Apr; 42(2):265-70. PubMed ID: 7627271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma.
    Hofstra RM; Fattoruso O; Quadro L; Wu Y; Libroia A; Verga U; Colantuoni V; Buys CH
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4176-8. PubMed ID: 9398735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
    Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
    Eng C; Foster KA; Healey CS; Houghton C; Gayther SA; Mulligan LM; Ponder BA
    Br J Cancer; 1996 Aug; 74(3):339-41. PubMed ID: 8695346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma.
    Bockhorn M; Frilling A; Kalinin V; Schröder S; Broelsch CE
    Langenbecks Arch Surg; 1999 Feb; 384(1):60-4. PubMed ID: 10367632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.